Roche Pharmaceutical Development and Sales Overview
YTD Sep 2022: Diagnostics Division highlights
Growing from a high base in 2021
CHFbn
Core Lab 1,3
Point of Care³
Molecular Lab³
Diabetes Care
-3%
Pathology Lab
+30%
-8%
YoY CER growth
+5%
• Immunodiagnostics (+6%)
• Clinical Chemistry (+8%)
• Custom biotech (-8%)³
.
⚫ POC Immunodiagnostics (+39%)
•
POC Molecular³ (+33%)
qPCR&NAP (-28%)
·
Virology (-7%)
.
• Blood glucose monitoring (-4%)
•
⚫ Insulin delivery systems (+9%)
• Advanced staining (+8%)
+10%
EMEA²
Asia-Pacific
North America
Latin America
•
Companion diagnostics (+28%)
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Roche
CER-Constant Exchange Rates; POC-point of care; 1 Underlying growth of Core Lab excluding Roche Information Solutions: +5%; 2 EMEA-Europe, Middle East and Africa; 3 Sales in Point of Care customer area include sales
from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information
for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23mCHF, Q4 21=20mCHF.
35View entire presentation